New research on patients with moderate-to-severe depression, who had not received adequate benefit from previous antidepressant therapy, demonstrated that NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy significantly improved quality of life and functioning when compared to patients receiving sham (placebo) treatment. The new data were presented today at the American Psychiatric Association's (APA) annual meeting.
"Symptom control is only meaningful in so far as it improves patients' ability to function and enjoy life, which is an essential part of the recovery process," said H. Brent Solvason, MD, Ph.D., Assistant Professor of Psychiatry at Stanford University. Dr. Solvason was a primary investigator in the NeuroStar TMS Therapy(TM) studies and is the lead author of this data report.
Read More
